MorphoSys Pins Hopes On Pelabresib For Near-Term Value After Tumultuous 2022
Cost-Cutting Measures In Place
Executive Summary
The German biotech has highlighted its myelofibrosis drug candidate, pelabresib, as a key value driver going forward after a year of hard knocks and lackluster Monjuvi sales that forced the firm to downsize its workforce and cease preclinical operations.
You may also be interested in...
MorphoSys Teams Up Again With Novartis For Preclinical Cancer Program
The German biotech announced in March that it was terminating the early-stage oncology R&D projects that came with its purchase of Constellation last year and Novartis has snapped up one of them.
MorphoSys Upbeat Despite Partner Failures In Alzheimer's And Rheumatoid Arthritis
Monjuvi is still struggling to make progress commercially and the hopes of lucrative royalty streams from partners Roche and GSK have dried up but MorphoSys is keeping faith in its fully owned pipeline.
Apellis Bounces Back After Needle Discontinuation Amid Syfovre Safety Concerns
Real-world cases of retinal vasculitis linked with Syfovre for geographic atrophy in age-related macular degeneration may have resulted from a material used in a specific filter needle, the US firm revealed, as analysts remained optimistic on the product.